Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 2/20 | 0.45 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10271367 | 0.90 | TNF (0.43) | RAB9ABRD4TNFKDM4ENPC1 | |
| SCHEMBL2687478 | 0.88 | TNF (0.58) | GALR3NR2F2RAB9ABRD4TNF | |
| SCHEMBL2688317 | 0.85 | HDAC1 (0.50) | RAB9ABRD4TNFKDM4ENPC1 | |
| SCHEMBL2688717 | 0.83 | SMN1; SMN2 (0.62) | RAB9AKDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL10270865 | 0.82 | TP53 (0.51) | RAB9ABRD4TNFKDM4ENPC1 | |
| SCHEMBL2687383 | 0.81 | KDM4E (0.55) | RAB9AKDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL2689288 | 0.80 | HPSE (0.46) | RAB9ATNFKDM4ENPC1ALDH1A1 | |
| SCHEMBL2688340 | 0.80 | KDM4E (0.43) | RAB9AKDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL3969688 | 0.79 | TNF (0.70) | GALR3NR2F2RAB9ATNFNPC1 | |
| SCHEMBL2686523 | 0.79 | KDM4E (0.48) | RAB9AKDM4ENPC1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115856-A1 | AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS | BDNF, NGF, NTRK2 | GALR3 123/4885NR2F2 184/4885RAB9A 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.